• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by XBiotech Inc.

    5/1/24 4:46:59 PM ET
    $XBIT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XBIT alert in real time by email
    DEFA14A 1 d715336ddefa14a.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to § 240.14a-12

    XBiotech Inc.

    (Name of Registrant as Specified In Its Charter)

    Payment of Filing Fee (Check the appropriate box)

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.

     

     

     


    LOGO

    XBiotech Inc. Thursday, June 20,2024 10:00 AM, Central Time Annual Meeting to be held live via the Internet - please visit www.proxydocs.com/XBIT for more details You must register to attend the meeting online and/or partidpate at wvew.proxydocs.com/XBIT For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/XBIT To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available shares. We to encourage you on the you Internet. to access This and is notreview a ballot. all ofYou the cannot important use this information notice to contained vote your in the proxy materials before voting. Under United States Securities and Exchange Commission rules, praxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting,you must make this request on or before June 10, 2024. Meeting Materials: Notce of Meeting and Proxy Statement & Annual Reportor Form 10-K To order paper materials, use one of the following methods. g www.investorelections.com/XBIT 1-866-648-8133 [email protected] * tfrequesing material by ermal, please send 2 blank emailwih he 12 digt contol number (located below) in he subject Ine. No other requests, instuctonsOR other inquiries should be incudedwith your email requesting masters Your control number Have the 12 digit control number located in the box above available when you access he website and follow the instructions. SEE REVERSE FOR FULL AGENDA Copyright © 2024 BetaNxT, Inc. or its affiliates. All Rights Reserved


    LOGO

    THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1,2 AND3 XBiotech Inc. Annual Meeting of Stockholders 1. To elect the five (5) nominees for director named herein to serve until the next annual meeting and their successors are duly elected and qualified. 1.01 John Simard 1.02 W. Thorpe McKenzie 1.03 Jan-Paul Waldin, Esq. 1.04 Donald H. MacAdam 1.05 Peter Libby, M.D. 2. To ratify the selection by the Audit Committee of the Board of Directors of Whitley Penn LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. 3. To approve, on an advisory basis, the compensation of the Company’s named executive officers. To conduct any other business properly brought before the meeting.

    Get the next $XBIT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XBIT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $XBIT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Rademaker Craig Evan

    4 - XBiotech Inc. (0001626878) (Issuer)

    11/12/25 9:56:03 AM ET
    $XBIT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Soffer David Spencer

    4 - XBiotech Inc. (0001626878) (Issuer)

    11/12/25 9:54:55 AM ET
    $XBIT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kuendig Thomas Martin

    4 - XBiotech Inc. (0001626878) (Issuer)

    11/12/25 9:53:42 AM ET
    $XBIT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XBIT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    XBiotech Pauses Rheumatology program

    AUSTIN, Texas, Dec. 23, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today data that it is halting its clinical program in rheumatological disease while it seeks to understand the outcome from its recently completed Phase II, Double-Blind, Placebo-Controlled, Randomized study in Rheumatoid Arthritis. The Phase II study failed to meet its primary endpoint amid substantial irregularities that make unequivocal interpretation of the findings difficult. XBiotech was planning launch of additional studies in arthritis as well as other areas of rheumatology, including ankylosing spondylitis, which are now on hold while recent findings are evaluated. About 230 subjects with modera

    12/23/24 9:00:00 AM ET
    $XBIT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

    AUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study examined Natrunix (anti-interleukin-1alpha) antibody in combination with an established chemotherapy regimen (ONIVYDE (ON) + 5-Fluorouracil (5FU) + Leucovorin (LV), a regimen that is already widely used for treating pancreatic cancer but is associated with difficult toxicities and less then ideal survival outcomes. Natrunix was being evaluated as an anti-cancer agent for use in cytotoxic chemotherapy combinations where the Company believes it might po

    6/18/24 11:35:14 AM ET
    $XBIT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

    AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it's campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site preparation and groundwork is expected to begin 1st quarter 2024. The new four-story building, to be located close to the existing 46,000 ft2 manufacturing and R&D facility, will provide key infrastructure to support commercialization plans for the company's Natrunix rheumatology program. The new 46,000+ft2 facility will house clinical and medical operations, commercialization teams, and even incorporate we

    1/4/24 9:00:00 AM ET
    $XBIT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XBIT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by XBiotech Inc.

    SCHEDULE 13G/A - XBiotech Inc. (0001626878) (Subject)

    1/23/26 4:33:19 PM ET
    $XBIT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XBiotech Inc. filed SEC Form 8-K: Leadership Update

    8-K - XBiotech Inc. (0001626878) (Filer)

    12/9/25 9:00:41 AM ET
    $XBIT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by XBiotech Inc.

    10-Q - XBiotech Inc. (0001626878) (Filer)

    11/12/25 11:45:33 AM ET
    $XBIT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XBIT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by XBiotech Inc. (Amendment)

    SC 13G/A - XBiotech Inc. (0001626878) (Subject)

    2/7/24 12:36:43 PM ET
    $XBIT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by XBiotech Inc. (Amendment)

    SC 13G/A - XBiotech Inc. (0001626878) (Subject)

    2/7/24 12:01:48 PM ET
    $XBIT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by XBiotech Inc. (Amendment)

    SC 13G/A - XBiotech Inc. (0001626878) (Subject)

    2/7/24 12:01:06 PM ET
    $XBIT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XBIT
    Financials

    Live finance-specific insights

    View All

    XBiotech Announces Payment of Dividend to Holders of Common Stock

    AUSTIN, Texas, July 30, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) ("XBiotech") has completed payment to holders of its Common Stock of a previously announced dividend in the amount of USD$75,000,000.00. Based on the number of shares of Common Stock issued and outstanding on the record date for the dividend, each such holder received USD$2.47 per share on July 23, 2021. In the past 18 months, XBiotech's balance sheet strength has enabled the company to offer approximately USD$495 million in cash to shareholders by way of stock repurchase and dividend distribution. The financial strength of the Company owes to the successful development of a pipeline of True Human™ antibody drug

    7/30/21 11:03:00 AM ET
    $XBIT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XBiotech Announces Dividend to Holders of Common Stock

    AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.'s (NASDAQ:XBIT) ("XBiotech") Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up to an aggregate of $75 million, to holders of its common stock. This one-time, special dividend will be payable on July 23, 2021 to stockholders of record at the close of business on July 16, 2021. "XBiotech's proven ability to develop highly valued drug candidates, revenue from contract operations, judicious deployment of operating capital, absence of debt, and very significant emerging opportunities in our pipeline, has created the balance sheet flexibility that enables us to provide shareholder

    7/6/21 4:30:00 PM ET
    $XBIT
    Biotechnology: Pharmaceutical Preparations
    Health Care